A5050919683- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Immune Cell Function and Interaction
- CNS Lymphoma Diagnosis and Treatment
- Histiocytic Disorders and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Multiple Myeloma Research and Treatments
- Polyomavirus and related diseases
- Pneumocystis jirovecii pneumonia detection and treatment
- Cutaneous Melanoma Detection and Management
- HIV/AIDS Research and Interventions
- Cervical Cancer and HPV Research
- Autoimmune and Inflammatory Disorders Research
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- vaccines and immunoinformatics approaches
- Cytomegalovirus and herpesvirus research
- Cancer Genomics and Diagnostics
Memorial Sloan Kettering Cancer Center
2010-2024
University of Arkansas for Medical Sciences
2009-2015
National Institutes of Health
2015
Johns Hopkins University
2009-2015
Cancer Research Center
2015
Case Western Reserve University
2010-2013
Georgetown University
2013
Georgetown University Medical Center
2013
Emmes (United States)
2011
Kettering University
2011
The availability of uniform and precise criteria for disease evaluation, response to treatment, clinical staging Kaposi's sarcoma (KS) in individuals with the acquired immune deficiency syndrome (AIDS) would facilitate therapeutic trials patients this neoplasm. Recently, a group oncologists conducting AIDS-associated KS as part cooperative established by National Institute Allergy Infectious Diseases (NIAID) drafted such criteria. take into account unique problems associated evaluation...
Preliminary clinical trials have shown that both natural and recombinant-DNA-produced human interferons are occasionally capable of inhibiting the growth some tumors.1 2 3 4 Although tumors responding to interferon most often been those without evidence for a viral association, case reports appeared therapeutic effects in patients with nasopharyngeal carcinoma,5 which there is strong serologic supporting laryngeal papilloma,6 available supports pathogenesis. Interferons also modify course...
PURPOSE Three trials were conducted to define the efficacy and toxicity of interferon alfa-2a in treatment metastatic renal cell cancer. Univariate multivariate analyses performed identify prognostic factors for survival. PATIENTS AND METHODS Prospectively, 159 patients treated with alfa-2a. In first trial, 42 received 50 x 10(6) U/m2 intramuscularly three times per week. second 64 gradually escalating doses from 3 36 U subcutaneously administered daily. The third trial was randomized; 25...
PURPOSE To prospectively validate the AIDS Clinical Trials Group (ACTG) staging classification for AIDS-associated Kaposi's sarcoma (KS). PATIENTS AND METHODS Two hundred ninety-four consecutive patients enrolled in eight ACTG therapeutic trials KS were staged according to tumor extent (T), severity of immunosuppression (I), and other systemic human immunodeficiency virus type 1 (HIV-1)-associated illness (S) observed survival. Patients classified as good risk (subscript 0) or poor 1) each...
Purpose Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it no more effective than standard dacarbazine. Extended TMZ dosing regimens may be superior by delivering the drug continuously at a higher dose over time. Using an extended schedule, we noted high incidence of lymphopenia and occasional opportunistic infections (OIs). Here report our retrospective experience first 97 patients. Materials Methods was...
Objective: To evaluate safety, tolerance, and potential efficacy of interferon-α zidovudine combination therapy in patients with Kaposi sarcoma the acquired immunodeficiency syndrome (AIDS). Design: Open, phase-I study randomization between two preparations interferon-α. Setting: Outpatient clinic a cancer research center. Patients: Forty-three associated AIDS. Interventions: Patients were treated 4.5, 9, or 18 million U/d, zidovudine, 100 200 mg orally every 4 hours. Measurements Main...
The efficacy of recombinant leukocyte A interferon (rIFN-alpha [Roferon-A, Hoffman-La Roche, Nutley, NJ]) treatment Kaposi's sarcoma in patients with acquired immunodeficiency syndrome was evaluated sequential trials using high doses (36 X 10(6) units) and low (3 interferon. major response seen 38% treated at the dose, a median duration 18 months. At rate 3%; dose escalation to 36 units resulted an additional 17% low-dose nonresponders, 10 Four 11 who achieved complete remain free disease,...
Abstract Purpose: Activation of the mitogen-activated protein kinase (MAPK) pathway and phosphatidylinositol 3-kinase/AKT seems to be critical for melanoma proliferation. Components these pathways are client proteins heat-shock 90 (hsp90), suggesting that inhibition hsp90 could have significant antimelanoma effects. We conducted a phase II trial using inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients. The primary end points were clinical responses whether treatment...
Purpose Matrix metalloproteinases (MMPs) are involved in tumor metastasis and overexpressed Kaposi's sarcoma (KS) cells. In a phase I trial of the MMP inhibitor COL-3 patients with AIDS-related KS, drug was well tolerated, KS regression observed, MMP-2 levels decreased significantly responders compared nonresponders. The aim this to extend these initial observations. Patients Methods This randomized, parallel-group, II study. administered orally once daily at one two doses (group A received...
Paclitaxel and pegylated liposomal doxorubicin (PLD) are active cytotoxic agents for the treatment of human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). A randomized trial comparing efficacy toxicity paclitaxel PLD was performed, effects therapy on symptom palliation quality life were determined.Patients with advanced HIV-associated KS randomly assigned to receive at a dose 100 mg/m2 intravenously (iv) every 2 weeks or 20 iv 3 weeks. The Functional Assessment HIV (FAHI)...
PURPOSE To determine the efficacy and safety of pegylated-liposomal doxorubicin in patients with AIDS Kaposi's sarcoma (AIDS-KS) who experienced failure standard chemotherapy. METHODS Fifty-three advanced AIDS-KS disease progression or intolerable toxicities while receiving doxorubicin/bleomycin/vincristine (ABV) bleomycin/vincristine (BV) chemotherapy were identified from a cohort then treated doxorubicin. Patients received 20 mg/m2 (Doxil; Sequus Pharmaceuticals, Inc, Menlo Park, CA) every...
Squamous cell carcinoma of the anal canal (SCCA) is etiologically linked to human papillomavirus, and its incidence increased among immunosuppressed. We used data from Surveillance, Epidemiology, End Results program analyze SCCA in relation 3 separate periods during HIV epidemic: pre-HIV era (1973-1981), (1982-1995), highly active antiretroviral treatment (HAART) (1996-2001). The per 100,000 population 0.6 0.8 1.0 HAART era. gap between women men decreased a ratio 1.6:1 1.5:1 1.2:1 There was...
PURPOSE: Matrix metalloproteinases (MMPs) are involved in tumor invasion and metastasis overexpressed Kaposi’s sarcoma (KS) cells. The primary aim was to define the safety toxicity of MMP inhibitor COL-3 patients with AIDS-related KS. Secondary aims were evaluate response, pharmacokinetics, changes blood levels MMP-2, MMP-9, vascular endothelial growth factor (VEGF), basic fibroblast (bFGF). PATIENTS AND METHODS: administered orally once daily, doses escalated cohorts three six subjects....
Purpose: To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases. Patients Methods: histologically confirmed advanced-stage were enrolled an open-label, phase II study. The primary end point was response rate. received (75 mg/m 2 /d × 6 weeks a 2-week rest between cycles) concomitant (200 mg/d dose escalation to 400 for < 70 years old, or 100 250 ≥ old). Treatment continued until unacceptable toxicity...
Studies with various interferon alpha preparations, including interferons induced in human leukocytes, alfa-N1, alfa-2a, and alfa-2b, have all provided evidence for modest but reproducible antitumor activity advanced renal cell carcinoma. Review of the data suggests that maximal response rates are achieved when is administered within a fairly restricted range moderate to high doses, whereas extremely low or dosage regimens appear less likely induce therapeutic response. Preliminary beta...
Interferon gamma (IFN-gamma) is a lymphokine with potent in vitro effects on cell growth and immune function. We have investigated the of rIFN-gamma (sp act approximately 2 X 10(7) U/mg, purity greater than 99%) 16 evaluable patients advanced malignancy phase 1 trial. Patients were treated six-hour intravenous (IV) infusions daily, five days week for weeks. After 2-week rest period, IV treatment cycle was repeated. Responders maintained repeated cycles or daily intramuscular (IM) injections....
Recombinant interferon gamma (rIFN-gamma) activates macrophage antimicrobial and antitumor functions related metabolic processes, including secretion of reactive oxygen intermediates in mice cultured mouse human macrophages. To look for similar actions man, we monitored the H2O2 secretory capacity monocytes from cancer patients receiving intravenous rIFN-gamma at 0.1, 0.5, or 1.0 mg/m2 body area over 6 hr daily 1 on alternate days. Monocytes taken just before first infusion served as...